OpenLB
Open Library of Bioscience
Advanced Search
Critical care (London, England)
06 24, 2019;23 (1): 231.

Individualized recombinant human thrombomodulin (ART-123) administration in sepsis patients based on predicted phenotypes.

Daisuke Hasegawa, Osamu Nishida
Author Information
  1. Daisuke Hasegawa: Department of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
  2. Osamu Nishida: Department of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. nishida@fujita-hu.ac.jp. ORCID
PMID: 31234901 DOI: 10.1186/s13054-019-2521-7

Abstract

No abstract text available.

References

  1. Blood. 2013 Oct 17;122(16):2784-94 [PMID: 24009232]
  2. J Intensive Care. 2016 Jul 22;4:48 [PMID: 27453785]
  3. Crit Care. 2018 Dec 18;22(1):347 [PMID: 30563548]
  4. JAMA. 2019 May 19;: [PMID: 31104069]
  5. JAMA. 2019 May 19;: [PMID: 31104070]

MeSH Term

Humans
Phenotype
Precision Medicine
Recombinant Proteins
Sepsis
Thrombomodulin

Chemicals

ART123
Recombinant Proteins
Thrombomodulin
Letter
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0IndividualizedrecombinanthumanthrombomodulinART-123administrationsepsispatientsbasedpredictedphenotypes

Similar Articles

Cited By